GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sapporo Clinical Laboratory Inc (TSE:9776) » Definitions » Debt-to-Equity

Sapporo Clinical Laboratory (TSE:9776) Debt-to-Equity : 0.20 (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Sapporo Clinical Laboratory Debt-to-Equity?

Sapporo Clinical Laboratory's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円261 Mil. Sapporo Clinical Laboratory's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円1,938 Mil. Sapporo Clinical Laboratory's Total Stockholders Equity for the quarter that ended in Mar. 2024 was 円10,937 Mil. Sapporo Clinical Laboratory's debt to equity for the quarter that ended in Mar. 2024 was 0.20.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sapporo Clinical Laboratory's Debt-to-Equity or its related term are showing as below:

TSE:9776' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.01   Max: 0.26
Current: 0.2

During the past 13 years, the highest Debt-to-Equity Ratio of Sapporo Clinical Laboratory was 0.26. The lowest was 0.01. And the median was 0.01.

TSE:9776's Debt-to-Equity is ranked better than
68.54% of 553 companies
in the Healthcare Providers & Services industry
Industry Median: 0.48 vs TSE:9776: 0.20

Sapporo Clinical Laboratory Debt-to-Equity Historical Data

The historical data trend for Sapporo Clinical Laboratory's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sapporo Clinical Laboratory Debt-to-Equity Chart

Sapporo Clinical Laboratory Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.23 0.26 0.23 0.20

Sapporo Clinical Laboratory Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.23 0.21 0.21 0.20

Competitive Comparison of Sapporo Clinical Laboratory's Debt-to-Equity

For the Pharmaceutical Retailers subindustry, Sapporo Clinical Laboratory's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sapporo Clinical Laboratory's Debt-to-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sapporo Clinical Laboratory's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sapporo Clinical Laboratory's Debt-to-Equity falls into.



Sapporo Clinical Laboratory Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sapporo Clinical Laboratory's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Sapporo Clinical Laboratory's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sapporo Clinical Laboratory  (TSE:9776) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Sapporo Clinical Laboratory Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sapporo Clinical Laboratory's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Sapporo Clinical Laboratory Business Description

Traded in Other Exchanges
N/A
Address
18-9-1 Nishi Kita-Gojo, Chuo-ku Sapporo, Hokkaido, Sapporo, JPN, 060 0005
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.

Sapporo Clinical Laboratory Headlines

No Headlines